Sector News

Perrigo CEO: Think Mylan’s buyout will come easily? Think again

August 7, 2015
Life sciences
Perrigo has stayed quiet since Teva dropped its hostile pursuit of Mylan, choosing instead to snap up Allergan’s generics business for $40.5 billion. Mylan’s shares plummeted on that news. And now, Perrigo has broken its silence–and the word isn’t what Mylan wants to hear.
 
Perrigo CEO Joseph Papa stuck to his company’s prior stance that Mylan’s $205-per-share bid “substantially undervalues” its business–and “the market movement following Teva’s announcement last week only reinforced” that conviction, he said during the company’s Q2 earnings call.
 
And if Mylan shareholders vote–at a special meeting later this month–to push forward with the Perrigo deal anyway? “If they proceed with a tender offer for Perrigo, this will not be the easy path that some are painting it to be,” he said, pointing out that the bar for success in the tender offer process is 80% of all outstanding Perrigo shares. ” … We’ll make a strategic decision with the board about what’s the right thing to do for the company,” he said.
 
The way some analysts see it, that’s still a big “if.” As Leerink Partners’ Jason Gerberry wrote in a recent note to investors, Mylan would have to bring its bid to about $230 per Perrigo share to make an “acceptable” offer for its target. And even if it can muster that, the potential tie-up “does not appear to create any value at prices above $205,” Cowen & Co. analyst Ken Cacciatore wrote late last month.
 
Meanwhile, Mylan topped Q2 earnings forecasts Thursday, posting EPS of 91 cents–2 cents better than analysts expected. Revenue of $2.37 billion fell short of analysts’ $2.39 billion forecast, however, despite year-over-year growth of 29%.
 
By Carly Helfand
 

comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach